Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants with Hematologic Malignancies (MK-1026-003)

Trial Identifier: 1026-003
Sponsor: MSD
Start Date: April 2021
Primary Completion Date: March 2027
Study Completion Date: March 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English
Protocol Plain Language Summary – English

Trial Locations